Anti-TNF Therapy Linked to Higher Survival in Crohn’s Patients, Study Reports

Anti-TNF Therapy Linked to Higher Survival in Crohn’s Patients, Study Reports
Anti-TNF therapy is associated with lower mortality rates compared to prolonged corticosteroid use in patients with Crohn's disease, researchers suggest. This reduced mortality may be linked to lower rates of major cardiovascular events or hip fractures. Also, the lower mortality rates seen in Crohn's patients were more significant in those with multiple or serious comorbidities. A comorbidity is one or more diseases that are happening at the same time as the primary condition — in this case, Crohn's disease. As the authors suggest, these patients are often excluded from clinical trials, yet they might benefit the most from anti-TNF therapy. "This population, which is rarely included in clinical trials and for whom some physicians may be reluctant to treat with chronic immunosuppression, may be particularly good candidates for anti-TNF agents as [corticosteroid-sparing] therapy," they wrote. The study, "Increased Mortality Rates With Prolonged Corticosteroid Therapy When Compared With Antitumor Necrosis Factor-α-Directed Therapy for Inflammatory Bowel Disease," was recently published in the American Journal of Gastroenterology. Inflammatory bowel disease (IBD) can include both Crohn's disease and ulcerative colitis (UC). Two of the main treatments used to control IBD symptoms include corticosteroids  and anti-tumor necrosis factor-α (anti-TNF) therapy. Despite growing evidence that corticosteroids are not as effective as anti-TNF therapy, they are still widely prescribed. This may stem partly from concer
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *